Medicine and Dentistry
Bladder Cancer
100%
Transitional Cell Carcinoma
76%
Neoplasm
72%
Malignant Neoplasm
24%
Metastatic Carcinoma
23%
Bladder
22%
Immunity
19%
Adenocarcinoma
18%
Diagnosis
18%
Cancer
18%
Thyroid Cancer
16%
Molecular Pathology
16%
Clinical Significance
16%
Diseases
14%
Pathologist
14%
Urogenital Tract Cancer
12%
Drive
12%
Prostate Cancer
11%
Immunohistochemistry
11%
Carcinoma
11%
Downregulation
10%
Pediatrics
10%
Ovarian Cancer
10%
Diffuse Large B-Cell Lymphoma
10%
Fungal Sinusitis
10%
Catenin
10%
Endometrial Hyperplasia
10%
Hyperplasia
9%
Nephroureterectomy
9%
Recurrent Disease
8%
Morphology
8%
Hazard Ratio
8%
Precursor
8%
Biopsy Technique
7%
Clinical Decision Making
7%
Biological Marker
7%
Peroxisome Proliferator Activated Receptor
6%
Programmed Death-Ligand 1
6%
Urothelium
6%
Reproducibility
6%
Cancer Cell
6%
Invasive Bladder Cancer
6%
Clear Cell Renal Cell Carcinoma
6%
Cancer Growth
6%
Differential Diagnosis
6%
Carcinoma in Situ
6%
Cancer Diagnosis
6%
Muscle Invasive Bladder Cancer
6%
Tumor Recurrence
5%
Kidney Tumour
5%
Keyphrases
Bladder Cancer
92%
Tumor
43%
Forkhead Box A1 (FOXA1)
41%
Molecular Subtypes
31%
Squamous Differentiation
26%
Histological Variants
23%
Invasive Urothelial Carcinoma
22%
Transcription Factor
19%
Urothelial Carcinoma
19%
Upper Tract Urothelial Carcinoma
17%
International Society of Urological Pathology
16%
Clinical Significance
14%
Prostate Cancer
13%
Thyroid Cancer
12%
Intratumoral Heterogeneity
12%
Muscle-invasive Bladder Cancer
12%
Papillary Urothelial Carcinoma
12%
Clinical Characteristics
11%
Immune Heterogeneity
10%
Consensus Conference
10%
Plastic Heterogeneity
10%
P120-catenin
10%
High-risk Human Papillomavirus (HR-HPV)
10%
Pediatric
10%
Molecular Pathology
10%
MicroRNA Profile
10%
On-state Current
10%
Frozen Section
10%
Endometrioid Adenocarcinoma
10%
Grading System
10%
Endometrial Hyperplasia
10%
Metastasis
10%
Urothelium
10%
Histologic
10%
Diagnostic Challenge
10%
Immunohistochemistry
9%
Non-muscle Invasive Bladder Cancer (NMIBC)
8%
Metastatic Urothelial Carcinoma
8%
Cancer Invasion
8%
Urothelial
8%
GATA3
8%
Poor Prognosis
8%
Programmed Death-ligand 1 (PD-L1)
8%
Histological Subtypes
8%
Bladder
8%
Urinary Bladder
8%
Fungi
8%
Cervical Cancer
8%
Histomorphology
7%
Hazard Ratio
7%